中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2008年
7期
875-877,封4
,共4页
宋自芳%郑启昌%尚丹%舒晓刚%熊俊%胡青刚
宋自芳%鄭啟昌%尚丹%舒曉剛%熊俊%鬍青剛
송자방%정계창%상단%서효강%웅준%호청강
arresten%重组蛋白%内膜增生%自体静脉移植
arresten%重組蛋白%內膜增生%自體靜脈移植
arresten%중조단백%내막증생%자체정맥이식
Arresten%Recombinant protein%Neointima hyperplasia%Autogenous vein graft
目的 观察原核表达人arresten重组蛋白对自体移植静脉内膜增生的抑制作用.方法 用pRSET原核表达系统表达并纯化人arresten重组蛋白.将Wistar大鼠颈外静脉移植于腹主动脉,建立大鼠自体静脉移植模型,实验分3组:假手术组、移植对照组和移植实验组.自术后第3天起,皮下注射给予arresten重组蛋白(每日4 mg/kg体重)处理.4周后取移植静脉组织标本,进行病理组织学观察与免疫组织化学染色分析.结果 移植组移植静脉均呈现典型的内膜增生、肥厚,导致血管管腔狭窄;新生内膜主要有过度增殖的α-SMA染色阳性平滑肌细胞组成.移植实验组移植静脉内膜增生受到明显抑制,新生内膜面积(0.12±0.07)mm2及新生内膜/中膜面积比(0.373±0.085)均显著低于对照组[(0.38±0.11)mm2,1.621±0.086,P<0.01];并且实验组移植静脉新生内膜细胞PCNA标记指数显著低于对照组[(15.62±3.97)%比(56.36±3.49)%,P<0.01].结论 重组arresten蛋白通过抑制新生内膜平滑肌细胞的增殖能有效抑制自体移植静脉内膜增生的发生发展,在防治血管重建术后再狭窄方面显示出良好的应用前景.
目的 觀察原覈錶達人arresten重組蛋白對自體移植靜脈內膜增生的抑製作用.方法 用pRSET原覈錶達繫統錶達併純化人arresten重組蛋白.將Wistar大鼠頸外靜脈移植于腹主動脈,建立大鼠自體靜脈移植模型,實驗分3組:假手術組、移植對照組和移植實驗組.自術後第3天起,皮下註射給予arresten重組蛋白(每日4 mg/kg體重)處理.4週後取移植靜脈組織標本,進行病理組織學觀察與免疫組織化學染色分析.結果 移植組移植靜脈均呈現典型的內膜增生、肥厚,導緻血管管腔狹窄;新生內膜主要有過度增殖的α-SMA染色暘性平滑肌細胞組成.移植實驗組移植靜脈內膜增生受到明顯抑製,新生內膜麵積(0.12±0.07)mm2及新生內膜/中膜麵積比(0.373±0.085)均顯著低于對照組[(0.38±0.11)mm2,1.621±0.086,P<0.01];併且實驗組移植靜脈新生內膜細胞PCNA標記指數顯著低于對照組[(15.62±3.97)%比(56.36±3.49)%,P<0.01].結論 重組arresten蛋白通過抑製新生內膜平滑肌細胞的增殖能有效抑製自體移植靜脈內膜增生的髮生髮展,在防治血管重建術後再狹窄方麵顯示齣良好的應用前景.
목적 관찰원핵표체인arresten중조단백대자체이식정맥내막증생적억제작용.방법 용pRSET원핵표체계통표체병순화인arresten중조단백.장Wistar대서경외정맥이식우복주동맥,건립대서자체정맥이식모형,실험분3조:가수술조、이식대조조화이식실험조.자술후제3천기,피하주사급여arresten중조단백(매일4 mg/kg체중)처리.4주후취이식정맥조직표본,진행병리조직학관찰여면역조직화학염색분석.결과 이식조이식정맥균정현전형적내막증생、비후,도치혈관관강협착;신생내막주요유과도증식적α-SMA염색양성평활기세포조성.이식실험조이식정맥내막증생수도명현억제,신생내막면적(0.12±0.07)mm2급신생내막/중막면적비(0.373±0.085)균현저저우대조조[(0.38±0.11)mm2,1.621±0.086,P<0.01];병차실험조이식정맥신생내막세포PCNA표기지수현저저우대조조[(15.62±3.97)%비(56.36±3.49)%,P<0.01].결론 중조arresten단백통과억제신생내막평활기세포적증식능유효억제자체이식정맥내막증생적발생발전,재방치혈관중건술후재협착방면현시출량호적응용전경.
Objective To investigate the inhibitory effect of prokaryotie-expressed arresten recombinant protein on neointimal hyperplasia of autogenous vein graft in rats. Methods Human arresten recombinant protein was expressed and purified from pRSET prokaryotic expression system. The model of autogenous vein graft was prepared by transplanting the external jugular vein into aorta in Wistar rats by means of micro-surgery. The rats were divided into three groups : sham operation group, autograft control group,autograft experimental group. From 3rd day after transplantation,arresten protein was injected intra-peritoneally daily at a dosage of 4 mg/(kg·d).Four weeks after treatment,venous autografts were removed at autopsy and subjected to histopathological examination and immanohistochemical staining. Results In autograft control and experimental groups,the venous autografts displayed well-developed neointimal proliferative lesions composed of a large number of smooth muscle cells that stained positive for α-SMA. The neointimal hyperplasia resulted in vascular lumen stricture in venous autografts. In autograft experimental group,the neointimal hyperplasia was suppressed obviously, and its neointimal area (0.12 ±0.07) mm2 and NIA/MA ratio (0.373 +0.085 ) of venous autografts were significantly reduced as compared with those in control group (0.38 + 0.11)mm2, 1.621±0.086 (P<0.01). And its PCNA labeling index of neointimal cells was significantly lower than that in control group (15.62±3.97) % vs (56.36±3.49) % (P<0.01). Conclusion Recombinant arresten protein could significantly inhibit the proliferation of neointimal smooth muscle cells and the development of neointimal hyperplasia of venous autografts in rats. Arresten is a powerful inhibitor of restenosis after vascular reconstructive operation with a potential for therapeutic use.